SAN DIEGO—(BUSINESS WIRE)—Feb. 24, 2015—ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, today
announced that it will present at the following investor conferences:
-
The Cowen and Company 35th Annual Health Care Conference on
Tuesday, March 3, 2015, at 10:40 a.m. Eastern Time in Boston,
Massachusetts.
-
The 27th Annual ROTH Conference on Tuesday, March 10, 2015,
at 10:00 a.m. Pacific Time in Laguna Niguel, California.
Live webcasts of these presentations will be accessible on the company’s
website, www.acadia-pharm.com,
under the investors section and an archived recording will be available
on the website for two weeks following the applicable presentation.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development and
commercialization of innovative medicines to address unmet medical needs
in neurological and related central nervous system disorders. ACADIA has
a pipeline of product candidates led by NUPLAZID™ (pimavanserin), for
which we have reported positive Phase III trial results in Parkinson’s
disease psychosis and which has the potential to be the first drug
approved in the United States for this disorder. Pimavanserin is also in
Phase II development for Alzheimer’s disease psychosis and has
successfully completed a Phase II trial in schizophrenia. ACADIA also
has clinical-stage programs for chronic pain and glaucoma in
collaboration with Allergan, Inc. and two preclinical programs directed
at Parkinson’s disease and other neurological disorders. All product
candidates are small molecules that emanate from internal discoveries.
ACADIA maintains a website at www.acadia-pharm.com
to which we regularly post copies of our press releases as well as
additional information and through which interested parties can
subscribe to receive e-mail alerts.
Forward-Looking Statements
Statements in this press release that are not strictly historical in
nature are forward-looking statements. These statements include but are
not limited to statements related to the progress and timing of ACADIA’s
drug discovery and development programs, either alone or with a partner,
including clinical trials, the benefits to be derived from ACADIA’s
product candidates, in each case including NUPLAZID (pimavanserin), and
the potential for NUPLAZID to be the first drug approved in the United
States for Parkinson’s disease psychosis. These statements are only
predictions based on current information and expectations and involve a
number of risks and uncertainties. Actual events or results may differ
materially from those projected in any of such statements due to various
factors, including the risks and uncertainties inherent in drug
discovery, development and commercialization, and collaborations with
others, and the fact that past results of clinical trials may not be
indicative of future trial results. For a discussion of these and other
factors, please refer to ACADIA’s annual report on Form 10-K for the
year ended December 31, 2013 as well as ACADIA’s subsequent filings with
the Securities and Exchange Commission. You are cautioned not to place
undue reliance on these forward-looking statements, which speak only as
of the date hereof. This caution is made under the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. All
forward-looking statements are qualified in their entirety by this
cautionary statement and ACADIA undertakes no obligation to revise or
update this press release to reflect events or circumstances after the
date hereof, except as required by law.
Source: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Steve Davis, Executive Vice
President,
Chief Financial Officer and Chief Business Officer
Lisa
Barthelemy, Director of Investor Relations
(858) 558-2871